依普沙坦治疗冠心病合并高血压的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 依普沙坦治疗冠心病合并高血压的临床观察
TITLE:
摘要: 目的:观察依普沙坦治疗冠心病合并高血压患者的疗效和安全性。 方法:160例冠心病合并高血压患者随机均分为观察组和对照组。两组患者均给予阿司匹林、硝酸甘油、低分子肝素、他汀类药物等常规治疗,对照组患者在常规治疗的基础上给予氯沙坦钾片50 mg,口服,每日1次;观察组患者在常规治疗的基础上给予依普沙坦片600 mg,口服,每日1次。两组疗程均为6个月。观察两组患者的临床疗效,治疗前后坐位收缩压、坐位舒张压、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、尿素(UREA)、肌酐(Cr)、尿酸(UA)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、简易精神状态量表(MMSE)评分、日常生活能力量表(ADL)评分及不良反应发生情况。结果:两组患者总有效率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者坐位收缩压、坐位舒张压、MMSE评分、ADL评分均显著低于同组治疗前,且观察组坐位收缩压低于对照组,差异均有统计学意义(P<0.05);两组患者坐位舒张压、MMSE评分、ADL评分组间比较,差异均无统计学意义(P>0.05);两组患者治疗前后ALT、AST、UREA、Cr、UA、TC、TG、HDL-C、LDL-C比较,差异均无统计学意义(P>0.05)。两组患者治疗期间均未见明显不良反应发生。 结论:依普沙坦可有效降低冠心病合并高血压患者坐位收缩压,改善认知功能,安全性较好。
ABSTRACT: OBJECTIVE:To observe the efficacy and safety of eprosartan in the treatment of hypertensive patients with coronary heart disease. METHODS: 160 hypertensive patients with coronary heart disease randomly divided into observation group and control group. All patients were given aspirin, nitroglycerin, low molecular weight heparin, statins and other conventional treatment; control group was additioanlly given 50 mg Losartan potassium tablet, orally, once a day. Observation group was additionally given 600 mg Eprosartan tablet, orally, once a day. The treatment course for both groups was 6 months. Clinical efficacy, sitting systolic blood pressure and diastolic blood pressure, alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea (UREA),creatinine(Cr),uric acid (UA),total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C),the Mini-Mental status (MMSE) scale and activities of daily living (ADL) scale scores before and after treatment and incidence of adverse reactions in 2 groups were observed. RESULTS: There was no significant difference in the total effective rate between 2 groups (P>0.05). After treatment, the sitting systolic blood pressure and diastolic blood pressure, MMSE and ADL scale scores in 2 groups were significantly lower than before, and sitting systolic blood pressure in observation group was lower than control group, the differences were statistically significant (P<0.05), and there were no significant differences in sitting diastolic blood pressure, MMSE and ADL scale scores between 2 groups (P>0.05), and no significant differences in ALT, AST, UREA, Cr, UA, TC, TG, HDL-C and LDL-C between 2 groups before and after treatment (P>0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS: Eprosartan can effectively reduce sitting systolic blood pressure in hypertensive patients with coronary heart disease, and improve cognitive function, with good safety.
期刊: 2016年第27卷第6期
作者: 刘军,王昕,邓骥,贾静,肖静
AUTHORS: LIU Jun,WANG Xin,DENG Ji,JIA Jing,XIAO Jing
关键字: 依普沙坦;冠心病;高血压;收缩压;坐位血压;认知功能
KEYWORDS: Eprosartan; Coronary heart disease; Hypertension; Systolic blood pressure; Sitting blood pressure; Cognitive function
阅读数: 379 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!